The end of twentieth century has introduced some changes into T helper (Th) cells division.
The identification of the new subpopulation of T helper cells producing IL-17 modified model …

The view of CD4 T‐cell‐mediated immunity as a balance between distinct lineages of Th1
and Th2 cells has changed dramatically. Identification of the IL‐17 family of cytokines and of …

Multiple sclerosis (MS) exhibits many of the hallmarks of an inflammatory autoimmune
disorder including breakdown of the blood‐brain barrier (BBB), the recruitment of …

In neuroinflammatory diseases, systemic (blood-borne) leukocytes invade the central
nervous system (CNS) and lead to tissue damage. A causal relationship between …

Abstract Recombinant interferon (IFN) β-1b was approved by the US Food and Drug
Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in …

Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease
of the central nervous system. The hallmark to MS is the demyelinated plaque, which …

Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss
of dopaminergic neurons, appearance of Lewy bodies and presence of neuroinflammation …

CD13/aminopeptidase N is a widely expressed ectoenzyme with multiple functions. As an
enzyme, CD13 regulates activities of numerous cytokines by cleaving their N-terminals and …

Interleukin 26 (IL-26) is the most recently identified member of the IL-20 cytokine subfamily,
and is a novel mediator of inflammation overexpressed in activated or transformed T cells …

Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central
nervous system. It is a heterogeneous pathology that can follow different clinical courses …